

FORM 3**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**OMB APPROVAL**

OMB Number: 3235-0104
 Estimated average burden
 hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>MARIO ERNEST</u> (Last) (First) (Middle) <u>C/O KINDRED BIOSCIENCES, INC.</u> <u>1555 BAYSHORE HIGHWAY, SUITE 200</u> (Street) <u>BURLINGAME CA</u> <u>94010</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>04/02/2018</u>	3. Issuer Name and Ticker or Trading Symbol <u>Kindred Biosciences, Inc. [KIN]</u> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
---	---	--	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	124,167	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	(1)	08/28/2023	Common Stock	833	1.37	D	
Stock Option (Right to Buy)	(2)	02/02/2024	Common Stock	37,000	15.41	D	
Stock Option (Right to Buy)	(3)	01/25/2025	Common Stock	44,000	6.96	D	
Stock Option (Right to Buy)	(4)	01/07/2026	Common Stock	44,000	3.45	D	
Stock Option (Right to Buy)	(5)	07/23/2027	Common Stock	20,000	7.65	D	

Explanation of Responses:

- The option vested in four equal quarterly installments following the grant date of August 29, 2013.
- The option vested in four equal quarterly installments following the grant date of February 3, 2014.
- The option vested in four equal quarterly installments following the grant date of January 26, 2015.
- The option vested in four equal quarterly installments following the grant date of January 8, 2016.
- 10,000 shares subject to the option vested in two equal quarterly installments on October, 24, 2017 and January 24, 2018. The remaining 10,000 shares subject to the option vest in two equal quarterly installments on April 24, 2018 and July 24, 2018.

/s/ Dietrick Miller, Attorney in Fact 04/11/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.